Vaccinex Beheer

Beheer criteriumcontroles 3/4

De CEO Vaccinex is Maurice Zauderer, benoemd in Apr2001, heeft een ambtstermijn van 23.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 430.28K, bestaande uit 95.7% salaris en 4.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 12.93K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 15.8 jaar en 20.8 jaar.

Belangrijke informatie

Maurice Zauderer

Algemeen directeur

US$430.3k

Totale compensatie

Percentage CEO-salaris	95.7%
Dienstverband CEO	23.6yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	15.8yrs
Gemiddelde ambtstermijn bestuur	20.8yrs

Recente managementupdates

Recent updates

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Aug 17

Analyse CEO-vergoeding

Hoe is Maurice Zauderer's beloning veranderd ten opzichte van Vaccinex's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$19m
Jun 30 2024	n/a	n/a	-US$18m
Mar 31 2024	n/a	n/a	-US$19m
Dec 31 2023	US$430k	US$412k	-US$20m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$425k	US$401k	-US$20m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$20m
Dec 31 2021	US$402k	US$375k	-US$22m
Sep 30 2021	n/a	n/a	-US$24m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	US$444k	US$357k	-US$29m
Sep 30 2020	n/a	n/a	-US$29m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$30m
Dec 31 2019	US$399k	US$347k	-US$32m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	n/a	n/a	-US$33m
Mar 31 2019	n/a	n/a	-US$31m
Dec 31 2018	US$337k	US$337k	-US$30m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$24m
Mar 31 2018	n/a	n/a	-US$23m
Dec 31 2017	US$408k	US$328k	-US$22m

Compensatie versus markt: De totale vergoeding ($USD 430.28K ) Maurice } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Maurice is gestegen terwijl het bedrijf verliesgevend is.

CEO

Maurice Zauderer (78 yo)

23.6yrs

Tenure

US$430,277

Compensatie

Dr. Maurice Zauderer, Ph.D. Co-Founded Vaccinex, Inc. in April 2001 and also serves as its President and Chief Executive Officer since April 2001. Dr. Zauderer serves as Director of Vaccinex Inc. since Apr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Maurice Zauderer	Co-Founder	23.6yrs	US$430.28k	0.13% $ 12.9k
Elizabeth Evans	COO and Senior VP of Discovery & Translational Medicine	3.5yrs	US$303.21k	0.0017% $ 165.0
Ernest Smith	Senior VP of Research & Chief Scientific Officer	15.9yrs	US$308.90k	0.0015% $ 140.1
Jill Sanchez	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
John Leonard	Senior Vice President of Development	15.8yrs	geen gegevens	0.00060% $ 57.6

15.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VCNX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 15.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Maurice Zauderer	Co-Founder	23.6yrs	US$430.28k	0.13% $ 12.9k
Bala Manian	Independent Director	19.9yrs	US$82.50k	0% $ 0
Gerald Van Strydonck	Independent Director	21.7yrs	US$90.00k	0.020% $ 1.9k
Anthony Tolcher	Scientific and Clinical Advisor	no data	geen gegevens	geen gegevens
Max Vasquez	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Mark Tullman	Scientific and Clinical Advisor	no data	geen gegevens	geen gegevens
Khurram Bashir	Scientific and Clinical Advisor	no data	geen gegevens	geen gegevens
Albert Friedberg	Chairman of the Board	23.6yrs	geen gegevens	0.078% $ 7.5k
Laura Balcer	Scientific & Clinical Advisor	no data	geen gegevens	geen gegevens
Peter Calabresi	Scientific & Clinical Advisor	no data	geen gegevens	geen gegevens
Barbara Yanni	Independent Director	9.8yrs	US$85.00k	0% $ 0
Jacob Frieberg	Independent Lead Director	9.8yrs	US$75.00k	0.063% $ 6.0k

20.8yrs

Gemiddelde duur

77.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VCNX zijn ervaren en ervaren (gemiddelde ambtstermijn van 20.8 jaar).

Vaccinex Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Insufficient new directors

Vaccinex, Inc., Annual General Meeting, May 12, 2022

Vaccinex, Inc. Announces Resignation of Raymond E. Watkins as Senior Vice President and Chief Operating Officer

Recent updates

Vaccinex, Inc. announced that it has received $2.149995 million in funding from Vaccinex (Rochester), L.L.C, FCMI Parent Co.

Vaccinex, Inc. Reports New Findings for Signal-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease Conference in Madrid, Spain

Vaccinex Receives Non-Compliance Letter Regarding Nasdaq Listing Rule 5550(b)(1)

New major risk - Financial position

Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership

Vaccinex, Inc. Reports Positive Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’S Disease

Insufficient new directors

Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease

Vaccinex, Inc. announced that it has received $1.75 million in funding

Vaccinex, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$43.68 loss per share (vs US$98.05 loss in FY 2022)

Vaccinex, Inc. announced that it expects to receive $1.49961 million in funding

Vaccinex, Inc. has filed a Follow-on Equity Offering.

Vaccinex Announces 1-for-14 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of The Nasdaq Capital Market

Vaccinex, Inc. announced that it expects to receive $3.700126 million in funding

New major risk - Market cap size

New major risk - Financial position

Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases

Vaccinex Receives Non-Compliance Notice From Nasdaq

Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs

Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study

Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer

Vaccinex, Inc. Provides Nasdaq Compliance Update

Vaccinex, Inc. announced that it has received $0.65 million in funding

New major risk - Financial position

New minor risk - Share price stability

Vaccinex Receives Letter from the Listing Qualifications Staff of the Nasdaq Notifying the Company No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

Vaccinex, Inc. announced that it has received $2.959999 million in funding from FCMI Parent Co.

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Insufficient new directors

Vaccinex, Inc. and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37Th Annual Meeting of Society for Immunotherapy of Cancer

Vaccinex Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Regarding Minimum Bid Requirement

First half 2022 earnings released: US$0.24 loss per share (vs US$0.47 loss in 1H 2021)

Insufficient new directors

Vaccinex, Inc., Annual General Meeting, May 12, 2022

Vaccinex, Inc. announced that it expects to receive $6.599997 million in funding

Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1B/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (Pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

Vaccinex, Inc. Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis

Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Price target decreased to US$7.00

Vaccinex, Inc.(NasdaqCM:VCNX) dropped from Russell Microcap Value Index

Vaccinex, Inc. Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease

Vaccinex, Inc. Announces Initiation of Phase 2 Clinical Trial with Merck’s anti-PD-1 therapy KEYTRUDA

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology

Vaccinex, Inc. Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform

Vaccinex, Inc. Announces Resignation of Raymond E. Watkins as Senior Vice President and Chief Operating Officer

Vaccinex, Inc. announced that it has received $7.474986 million in funding from FCMI Parent Co., Vaccinex (Rochester), L.L.C and other investors

Vaccinex, Inc. Announces Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of Pepinemab

Vaccinex, Inc. announced that it expects to receive $2 million in funding

Vaccinex, Inc. announced that it has received $8 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd